Psychostimulant abuse has been characterized by persistent changes in brain dopamine (DA) activity. Recently, we developed a novel pharmacologic strategy predicated on the understanding that GABA inhibits DA and other neurotransmitter systems. Specifically, gamma-vinyl GABA (GVG, vigabatrin), inhibits drug self-administration, the expression and acquisition of conditioned place preference and sensitization, the lowering of drug-induced brain stimulation reward thresholds and drug induced increases in synaptic and extracellular DA. Through irreversible inhibition of GABA-transaminase (GABA-T), the enzyme responsible for GABA catabolism, GVG provides a non-receptor mediated mechanism with a duration of effect on GABA-T that parallels the time required to synthesize new enzyme. However, the duration of GVG's effect on GABA levels does not parallel this time course. Further, when properly scheduled, GVG possesses a use-dependent mechanism such that increases in brain GABA are utilized only in the presence of abnormal stimulation. GVG pharmacotherapy represents the possibility of an approach unparalleled in duration and specificity. Under the premise that useful medications for cocaine or nicotine dependence also require a therapy that can treat withdrawal symptoms and block the euphoria associated with drug self-administration, we propose that the dosing intensity and duration of GVG's pharmacologic activity can be optimized to help maintain an extended, drug-free lifestyle. We intend to use in vivo microdialysis in rodents to measure the effects of several subchronic, low-dose GVG treatment schedules on the DA response to a cocaine or nicotine challenge following extended washout durations. Further, using the conditioned place preference (CPP) paradigm as an index of craving, we propose to explore the effects of similar treatment schedules and washout durations on drug seeking behavior. This development represents an identified therapeutic strategy for the treatment of psychostimulant abuse symptoms associated with their toxic effects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA015041-02
Application #
6669086
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Acri, Jane
Project Start
2002-09-30
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
2
Fiscal Year
2003
Total Cost
$241,500
Indirect Cost
Name
Brookhaven National Laboratory
Department
Type
DUNS #
027579460
City
Upton
State
NY
Country
United States
Zip Code
11973
Mirrione, Martine M; Konomos, Dorothy K; Gravanis, Iordanis et al. (2010) Microglial ablation and lipopolysaccharide preconditioning affects pilocarpine-induced seizures in mice. Neurobiol Dis 39:85-97
Pothakos, Konstantinos; Robinson, John K; Gravanis, Iordanis et al. (2010) Decreased serotonin levels associated with behavioral disinhibition in tissue plasminogen activator deficient (tPA-/-) mice. Brain Res 1326:135-42
DeMarco, Amy; Dalal, Reema M; Pai, Jessica et al. (2009) Racemic gamma vinyl-GABA (R,S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference. Synapse 63:87-94
Schiffer, Wynne K; Liebling, Courtney N B; Reiszel, Corinne et al. (2009) Cue-induced dopamine release predicts cocaine preference: positron emission tomography studies in freely moving rodents. J Neurosci 29:6176-85
Patel, Vinal D; Lee, Dianne E; Alexoff, David L et al. (2008) Imaging dopamine release with Positron Emission Tomography (PET) and (11)C-raclopride in freely moving animals. Neuroimage 41:1051-66
Lee, Dianne E; Pai, Jennifer; Mullapudui, Uma et al. (2008) The effects of inhaled acetone on place conditioning in adolescent rats. Pharmacol Biochem Behav 89:101-5
DeMarco, Amy; Dalal, Reema M; Kahanda, Milan et al. (2008) Subchronic racemic gamma vinyl-GABA produces weight loss in Sprague Dawley and Zucker fatty rats. Synapse 62:870-2
Marsteller, Douglas A; Barbarich-Marsteller, Nicole C; Patel, Vinal D et al. (2007) Brain metabolic changes following 4-week citalopram infusion: increased 18FDG uptake and gamma-amino butyric acid levels. Synapse 61:877-81
Mirrione, Martine M; Schiffer, Wynne K; Fowler, Joanna S et al. (2007) A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 38:34-42
Schiffer, Wynne K; Liebling, Courtney N B; Patel, Vinal et al. (2007) Targeting the treatment of drug abuse with molecular imaging. Nucl Med Biol 34:833-47

Showing the most recent 10 out of 20 publications